Enable Injections has entered into a development agreement with Genentech. This partnership includes the potential for multiple molecule development programs including enFuse, under development by Enable to enable patient-administered subcutaneous delivery of high-volume therapeutics.
Enable’s enFuse is an on-body drug delivery platform with a drug transfer system compatible with standard syringes or vial container formats. The wearable enFuse platform is being developed for subcutaneous administration of large-volumes potentially ranging up to 50 mL. Designed for ease of use, enFuse has the potential to provide patients and their caregivers an alternative delivery method for subcutaneous administration of parenteral therapies outside of a clinical setting.
“Enable Injections is pleased to partner with Genentech in its focus on delivering patient-focused solutions,”
said Michael Hooven, president and chief executive officer, Enable Injections.
“With the enFuse paired to deliver selected subcutaneous therapeutics, it can potentially benefit patients worldwide.”